Articles with public access mandates - Josep M LlovetLearn more
Not available anywhere: 17
Review
Immunotherapies for hepatocellular carcinoma
JM Llovet, F Castet, M Heikenwalder, MK Maini, V Mazzaferro, DJ Pinato, ...
Nature reviews Clinical oncology 19 (3), 151-172, 2022
Mandates: US National Institutes of Health, German Research Foundation, Cancer …
Review
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design
M Burrel, M Reig, A Forner, M Barrufet, CR de Lope, S Tremosini, ...
Journal of hepatology 56 (6), 1330-1335, 2012
Mandates: US National Institutes of Health, Government of Spain
Review
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
JM Llovet, T De Baere, L Kulik, PK Haber, TF Greten, T Meyer, R Lencioni
Nature reviews Gastroenterology & hepatology 18 (5), 293-313, 2021
Mandates: US Department of Defense, US National Institutes of Health, German Research …
Review
Mutational landscape of HCC—the end of the beginning
A Villanueva, JM Llovet
Nature reviews Clinical oncology 11 (2), 73-74, 2014
Mandates: US National Institutes of Health, Government of Spain
Review
Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
J von Felden, AJ Craig, T Garcia-Lezana, I Labgaa, PK Haber, D D’Avola, ...
Oncogene 40 (1), 140-151, 2021
Mandates: Swiss National Science Foundation, US Department of Defense, US National …
Review
Effect of HCV clearance with direct-acting antiviral agents on HCC
JM Llovet, A Villanueva
Nature Reviews Gastroenterology & Hepatology 13 (10), 561-562, 2016
Mandates: European Commission, Government of Spain
Review
Time to evolve trial design after everolimus failure
JM Llovet
Nature reviews Clinical oncology 11 (9), 506-507, 2014
Mandates: US National Institutes of Health, Government of Spain
Review
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials
JM Llovet, J Bruix
Journal of Clinical Oncology 27 (6), 833-835, 2009
Mandates: US National Institutes of Health
Review
Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies
M Kudo, R Montal, RS Finn, F Castet, K Ueshima, N Nishida, PK Haber, ...
Clinical Cancer Research 28 (16), 3443-3451, 2022
Mandates: US Department of Defense, US National Institutes of Health, Cancer Research …
Review
Integration of genomic information in the clinical management of HCC
IM Quetglas, A Moeini, R Pinyol, JM Llovet
Best Practice & Research Clinical Gastroenterology 28 (5), 831-842, 2014
Mandates: US National Institutes of Health, Government of Spain
Review
Genome-scale metabolic models for hepatocellular carcinoma
R Pinyol, JM Llovet
Nature Reviews Gastroenterology & Hepatology 11 (6), 336-337, 2014
Mandates: US National Institutes of Health, Government of Spain
Review
Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: results from a prospective phase 2 trial
M Buckstein, E Kim, U Özbek, P Tabrizian, G Gunasekaran, M Facciuto, ...
International Journal of Radiation Oncology* Biology* Physics 114 (2), 221-230, 2022
Mandates: US National Institutes of Health, Cancer Research UK, Government of Spain …
Review
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
JM Llovet, R Pinyol, M Yarchoan, AG Singal, TU Marron, M Schwartz, ...
Nature Reviews Clinical Oncology 21 (4), 294-311, 2024
Mandates: Cancer Research UK, European Commission
Review
Exploring a new pathway for biomarker-based approval of immunotherapies
JM Llovet
Nature Reviews Clinical Oncology 20 (5), 279-280, 2023
Mandates: US National Institutes of Health, Cancer Research UK, Government of Spain …
Review
Genetics of hepatocellular carcinoma: risk stratification, clinical outcome, and implications for therapy
I Labgaa, S Torrecilla, I Martinez-Quetglas, D Sia
Digestive Disease Interventions 1 (02), 055-065, 2017
Mandates: Swiss National Science Foundation, Government of Spain
Review
Reply to:“mRECIST for systemic therapies: More evidence is required before recommendations could be made”
R Montal, R Lencioni, JM Llovet
Journal of hepatology 67 (1), 196-197, 2017
Mandates: US Department of Defense, European Commission, Government of Spain
Review
HIMALAYA Overall Survival Prominence and Other Routes to the Peak—Reply
JM Llovet, S Cappuyns, RS Finn
JAMA oncology 10 (3), 1-1, 2024
Mandates: Cancer Research UK
Available somewhere: 168
Review
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
R Lencioni, JM Llovet
Seminars in liver disease 30 (01), 052-060, 2010
Mandates: US National Institutes of Health
Review
Design and endpoints of clinical trials in hepatocellular carcinoma
JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu, ...
Journal of the National Cancer Institute 100 (10), 698-711, 2008
Mandates: US National Institutes of Health
Review
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
K Schulze, S Imbeaud, E Letouzé, LB Alexandrov, J Calderaro, ...
Nature genetics 47 (5), 505-511, 2015
Mandates: US Department of Energy, German Research Foundation, National Institute of …
Publication and funding information is determined automatically by a computer program